Three-Year Clinical Outcome and Quality of Life Interim Analysis of a Phase 2 Trial to Examine Use of Postchemotherapy Volumes After Neoadjuvant Treatment of Squamous Cell Carcinomas of the Head and Neck
Jennifer Ma(Jackson Memorial Hospital), S. Vijayakumar(University of Mississippi Medical Center), Karen T. Pitman(University of Mississippi Medical Center), R. Jennelle(University of Southern California), Gina D. Jefferson(University of Mississippi Medical Center), J.J. Caudell(Moffitt Cancer Center), Robert D. Hamilton(University of Mississippi Medical Center), Kristen J. Otto(Moffitt Cancer Center), W.F. Mourad(Mount Sinai Beth Israel)
International Journal of Radiation Oncology*Biology*Physics
September 1, 2014
Cited by 0
Related Papers
Diagnosis and Management of Squamous Cell Carcinoma of Unknown Primary in the Head and Neck: ASCO Guideline
|Journal of Clinical Oncology|2020|221
Dose-Limiting Pulmonary Toxicity in a Phase 1/2 Study of Radiation and Chemotherapy with Ipilimumab Followed by Nivolumab for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer
|International Journal of Radiation Oncology*Biology*Physics|2023|18
A phase II, randomized study of nivolumab (NIVO) and Ipilimumab (IPI) versus NIVO, IPI and stereotactic body radiation therapy (SBRT) for metastatic Merkel cell carcinoma (MCC, NCT03071406): A preliminary report
|Annals of Oncology|2019|5
NBTXR3 Radiation Enhancing Hafnium Oxide Nanoparticles Activated By Radiotherapy In Combination With Anti-PD-1 Therapy: A Phase I Study
|International Journal of Radiation Oncology*Biology*Physics|2020|4
Kinetics of Circulating Human Papillomavirus (cHPV) DNA in Plasma and Oral Gargles From Patients with HPV-Positive Oropharyngeal Cancer (OPC) Treated with Definitive Radiation Therapy
|International Journal of Radiation Oncology*Biology*Physics|2022|2